Paul Maher

Experience: Representative Matters: Advised Bracco Imaging S.p.A., an Italian manufacturer of agents and tracers used in diagnostic imaging, in the $450 million acquisition of Blue Earth Diagnostics Limited, a company which specializes in developing molecular imaging agents used in PET scans, from Syncona Portfolio Limited, subject to a $25 million closing adjustment.; Advised Paul Barry, the majority shareholder of Cambridge United Football Club Limited (CUFC), on his acquisition of all the remaining shares in CUFC to become the football club's sole shareholder.; Advised KIPCO in transaction related advice. The deal involved providing periodic strategic and English law contractual advice on the corporate aspects of a Middle East-based joint venture in which the client is the majority shareholder, including the corporate aspects associated with a material debt financing of the JV company.; Advised AstraZeneca AB on its agreement with Grunenthal to divest the European rights to Nexium for an upfront payment of $700 million with further sales-related and milestone payments of up to $90 million.; Advised AstraZeneca AB on its agreement with Grunenthal to divest the global rights to Vimovo in all markets excluding the United States and Japan for an upfront payment of $115 million and further payments up to another $17 million.; Advised Taiyo Nippon Sanso Corporation, a Japanese-based industrial gas producer, and its subsidiary Matheson Tri-Gas, in connection with its 5 billion acquisition of Praxair's European industrial gas business.; Advised of Rentokil Initial plc the world's leading commercial pest control services provider on the worldwide acquisition of Cannon Hygiene business from OCS Group Limited.; Advised Smiths Group plc on the sale of Smiths Interconnect's Microwave Telecoms business to Infinite Electronics Incfor US$112.5m.; Advised Rentokil Initial plc on its joint venture agreement with Haniel & Cie. Holding Company which created a leading provider of workwear and hygiene services in Europe with combined revenues of c. 1.1bn.; Advised Rentokil Initial plc on its joint venture with PCI Pest Control Pvt. Ltd., creating the largest provider of pest control services and products in India.; Advised AstraZeneca plc on the sale of its small molecule antibiotics business to Pfizer for US$725m.; Advised AB Volvo on the sale of its North American construction equipment rental business to Platinum Equity for $1.1bn.; Advised Rentokil Initial plc on the sale of its Initial Facilities business to Interserve plc for 250m.; Advised AB Volvo on the sale of its Volvo Aero aircraft engines business to GKN (Holdings) plc for 700m.; Advised AstraZeneca plc on its US$1.15bn (740m) acquisition of Pearl Therapeutics, a privately held US company developing inhaled combination therapies for the treatment of respiratory diseases.; Advised Rentokil Initial plc on its sale of City Link Limited to BECAP12 Fund LP (Better Capital), a private equity investor.; Advised AstraZeneca plc on its agreement to sell its AstraTech business to Dentsply for $1.8bn.; Advised Smiths Group plc in relation to its joint venture with Analogic.; Advised Healthcor, 3i and senior management of ApaTech Limited in its US$330m sale to global health care company Baxter International Inc.; Advised Dutch food company Vion in its purchase of a majority shareholding in J&J Tranfield.; Advised AstraZeneca plc in connection with its equity investment in the AIM-listed Silence Therapeutics.; Advised AstraZeneca plc and its subsidiary Cambridge Antibody Technology Limited in the disposal by CAT of its Humira royalty stream to Royalty Pharma.; Advised shareholders of The Mergermarket Group on their agreement to sell the entire issued share capital of Pearson plc.; Advised Imperial Chemical Industries plc (ICI) on its agreement to sell its Uniqema manufacturing to Croda International plc.; Advised Bear Stearns and its subsidiary BSG Insurance Holdings on the acquisition of Minster Insurance Services from Groupama UK for an undisclosed sum.; Advised senior management on the sale of Financial Dynamics to FTI Consulting Inc.; Advised Cambridge Antibody Technology Group plc on its recommended cash offer by AstraZeneca for its entire issued and to-be-issued share capital.; Advised Etex SA on the disposal of its Thermalite division to Hanson.; Advised Danske Bank on its acquisition of Northern Bank and National Irish Bank from National Australia Bank.; Advised Wittington Investments on its recommended offer for Selfridges plc.; Advised ICI plc on the sale of the U.S., Canadian and European Vinamul Polymers business National Starch and Chemical (NSC) Company to Celanese. (NSC is a business unit of ICI.); Advised GE on its recommended offer for Druck Holdings plc.; Advised Cable & Wireless plc on its purchase of UK-based broadband service provider Bulldog Communications Limited.; Advised Monsanto Company and its subsidiaries on the disposal of its European wheat and barley seed business to RGAT Genetique S.A.; Advised Cambridge Antibody Technology Group plc on its proposed takeover of Oxford GlycoSciences plc to be effected by way of a scheme of arraignment.; Certain of the above representations were handled by Mr. Maher prior to his joining Greenberg Traurig, LLP.; In-House Experience: In-house lawyer, Imperial Chemical Industries (ICI) PLC, 1984-1990